Vischer advises Redbiotec on its agreement with Eurocine for HSV-2 vaccines

Eurocine Vaccines and Redbiotec have signed a research and collaboration agreement for the development of vaccine candidates against herpes simplex virus type 2. Under the terms of the agreement, Eurocine will have exclusive international rights to develop, manufacture and commercialise the vaccines. On the other hand, the vaccines are being developed using Redbiotec’s technologies. The agreement includes both mRNA and protein-based technologies for the herpesvirus domain (HSV-2). HSV-2 is a sexually transmitted disease that is primarily treated with antivirals. There is currently no effective therapeutic vaccine on the market, hence the importance of the agreement.

VISCHER has supported Redbiotec in this partnership. The team has been led by corporate partner Matthias Staehelin (pictured left) and Christoph Enz (associate, pictured right).

Vischer advises Redbiotec on its agreement with Eurocine for HSV-2 vaccines


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram